Sleep Health in Women: Insomnia, Sleep Disorders, and Hormonal Factors

Sleep disorders affect women at disproportionately higher rates than men across multiple life stages, with hormonal transitions — from menstruation through menopause — functioning as documented physiological drivers of disrupted sleep architecture. This page covers the classification of sleep disorders most relevant to women's health, the mechanisms through which hormones alter sleep, the clinical scenarios where disruption is most pronounced, and the decision framework clinicians use to distinguish primary sleep disorders from hormonally mediated ones. Understanding these distinctions matters because misclassification leads to treatment strategies that address symptoms while leaving underlying endocrine causes unresolved. The broader Women's Health Authority addresses sleep as one component of integrated women's health.

Definition and scope

Sleep health, as defined by the National Sleep Foundation, encompasses sleep duration, continuity, timing, alertness, and subjective satisfaction — five dimensions that can each be independently disrupted. The American Academy of Sleep Medicine (AASM), which publishes the International Classification of Sleep Disorders (ICSD-3), recognizes insomnia disorder, sleep-related breathing disorders, central disorders of hypersomnolence, circadian rhythm sleep-wake disorders, parasomnias, and sleep-related movement disorders as the six major diagnostic categories (AASM ICSD-3).

Women are approximately 40% more likely than men to report insomnia symptoms, according to data published by the National Institutes of Health (NIH Sleep Research). That disparity is not uniform across age — it widens during pregnancy, the postpartum period, and the menopausal transition, pointing toward endocrine mechanisms rather than behavioral ones alone.

Sleep disorders that carry specific clinical relevance for women include:

  1. Chronic insomnia disorder — defined by the AASM as difficulty initiating or maintaining sleep at least 3 nights per week for at least 3 months, with associated daytime impairment
  2. Obstructive sleep apnea (OSA) — historically underdiagnosed in women because symptom presentation (fatigue, insomnia, mood changes) differs from the male pattern (loud snoring, witnessed apnea)
  3. Restless legs syndrome (RLS) — occurs at twice the prevalence in women compared to men, with iron deficiency and pregnancy identified as precipitating factors (NIH National Institute of Neurological Disorders and Stroke)
  4. Circadian rhythm sleep-wake disorders — including delayed sleep-wake phase disorder, which affects women differently across reproductive stages
  5. Nightmare disorder and REM sleep behavior disorder — more prevalent in women with post-traumatic stress disorder (PTSD), a condition the U.S. Department of Veterans Affairs notes disproportionately affects women

The regulatory context for women's health in the United States frames sleep disorders under the umbrella of conditions requiring sex-disaggregated research, following the NIH Revitalization Act of 1993, which mandated inclusion of women in federally funded clinical research.

How it works

The relationship between hormones and sleep operates through at least four distinct biological pathways.

Estrogen and progesterone both bind to receptors in the hypothalamus and brainstem regions governing sleep-wake transitions. Progesterone has a demonstrated sedative effect through its conversion to allopregnanolone, a positive allosteric modulator of GABA-A receptors — the same receptor class targeted by benzodiazepines. The sharp drop in progesterone during the late luteal phase of the menstrual cycle and after parturition is mechanistically linked to heightened sleep fragmentation at those time points.

Estrogen modulates serotonin and norepinephrine signaling, both of which regulate REM sleep architecture. Declining estrogen in perimenopause and postmenopause reduces the threshold for vasomotor events (hot flashes and night sweats), which the North American Menopause Society identifies as the primary sleep disruptors during the menopausal transition (NAMS Clinical Practice Guidelines). Polysomnographic studies have recorded objective sleep disruption coinciding with skin conductance spikes associated with hot flash events.

Cortisol follows a diurnal rhythm regulated by the hypothalamic-pituitary-adrenal (HPA) axis. HPA axis dysregulation, which is more common in women with major depressive disorder or anxiety — two conditions with higher female prevalence — flattens the cortisol morning peak and elevates evening cortisol, directly impairing sleep onset.

Thyroid hormones at abnormal levels, whether hyperthyroid or hypothyroid, alter metabolic rate, body temperature, and heart rate in ways that independently disrupt sleep continuity. Thyroid disorders occur at 5 to 8 times higher rates in women than men, according to the American Thyroid Association (ATA), making this a clinically non-trivial intersection. Additional detail on that relationship is covered on the thyroid disorders in women page.

Common scenarios

Premenstrual and PMDD-related insomnia: In the 7 to 10 days preceding menstruation, the luteal phase drop in progesterone and accompanying allopregnanolone withdrawal produces measurable reductions in GABA-A activity. Women with premenstrual dysphoric disorder (PMDD) show objectively shorter REM latency and more fragmented slow-wave sleep in polysomnographic studies compared to those without PMDD.

Pregnancy-related sleep disruption: The NIH reports that more than 78% of pregnant women experience sleep disruption, attributable to a combination of mechanical factors (fetal movement, nocturia, musculoskeletal discomfort) and hormonal shifts. Progesterone's relaxant effect on upper airway musculature elevates OSA risk in the third trimester. RLS occurs in approximately 26% of pregnant women, according to the NINDS, compared to roughly 5 to 10% of the general adult population.

Postpartum insomnia: The postpartum period combines abrupt hormonal withdrawal — estrogen and progesterone fall within 24 hours of delivery — with circadian disruption from infant care schedules. The overlap with postpartum depression, addressed on the postpartum depression and mood disorders page, requires clinical differentiation because the two conditions reinforce each other.

Perimenopause and menopause: The Study of Women's Health Across the Nation (SWAN), a multi-site longitudinal study funded by the NIH, found that 40% of perimenopausal women and 56% of postmenopausal women reported insomnia symptoms (SWAN Data). Vasomotor symptoms account for a measurable portion of this disruption, but sleep architecture changes — reduced slow-wave sleep and increased stage 1 sleep — also occur independently of hot flash frequency.

OSA underdiagnosis in women: Female OSA presentation frequently involves insomnia, fatigue, morning headache, and mood disturbance rather than the loud snoring pattern used in classical screening tools. The STOP-BANG questionnaire, widely used in clinical settings, was validated primarily on male populations, which the AASM has acknowledged as a screening gap.

Decision boundaries

Clinicians and researchers distinguish between three categories when evaluating sleep problems in women, with treatment pathways diverging substantially at each boundary.

Category 1 — Primary sleep disorder with no identified hormonal driver: Chronic insomnia disorder meeting ICSD-3 criteria, persisting independent of menstrual cycle phase, pregnancy status, or hormonal transition. First-line treatment per AASM guidelines is Cognitive Behavioral Therapy for Insomnia (CBT-I), which the AASM rates as having the strongest evidence base (AASM Clinical Guidelines for Chronic Insomnia). Pharmacologic options are adjunctive.

Category 2 — Sleep disruption as a direct consequence of hormonal transition: Insomnia or sleep fragmentation that intensifies in the late luteal phase, during pregnancy, postpartum, or through the menopausal transition. The clinical question is whether to address the sleep symptoms directly or the underlying hormonal driver. For menopausal vasomotor-driven insomnia, NAMS guidelines indicate that hormone therapy is appropriate for certain candidates, reducing hot flash frequency and secondarily improving sleep.

Category 3 — Sleep disorder co-occurring with a psychiatric or medical condition: Major depressive disorder, anxiety disorders, PTSD, thyroid disease, or chronic pain each impair sleep through mechanisms independent of, or compounding, hormonal factors. The DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) and the International Classification of Diseases, Eleventh Revision (ICD-11) both specify that insomnia disorder can be diagnosed concurrently with a comorbid condition rather than being attributed to it — a shift from prior nomenclature that had classified insomnia as "secondary" to the primary diagnosis.

The distinction between categories matters clinically because treating Category 2 with CBT-I alone may be insufficient if vasomotor events are generating 8 to 12 awakenings per night, and treating Category 1 with hormone therapy carries unnecessary risk if no endocrine driver is present. Sleep diary data over 14 days, actigraphy, and in selected cases polysomnography are the standard instruments used to establish which boundary applies.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)